Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jul 23, 2026
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 7% Since Last Earnings Report?
12:59pm, Thursday, 23'rd Mar 2023
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?
These Are the Top 10 Holdings of David Kim
10:55pm, Monday, 06'th Mar 2023
David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 20
Wall Street Upgraded This Stock's Price Target After a New Approval: Is It a Buy?
09:05am, Monday, 27'th Feb 2023
The company's lead therapy was just approved for another indication.
Why Apellis Pharmaceuticals Stock Surged This Week
06:08pm, Friday, 24'th Feb 2023
A highly eventful five days for the company saw bulls pile into its shares.
Apellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues
03:03pm, Wednesday, 22'nd Feb 2023
Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Tops Revenue Estimates
07:34pm, Tuesday, 21'st Feb 2023
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of 9.09% and 8.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for th
Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval
11:53am, Tuesday, 21'st Feb 2023
Apellis Pharmaceuticals snagged FDA approval for the first-ever geographic atrophy treatment, leading APLS stock to surge Tuesday. The post Apellis Surges To Four-Month High — Sending Rival Iveric T
Apellis: Empaveli Ought To Win Approval For Eye Disease In February - The Future Looks Bright
12:29pm, Friday, 27'th Jan 2023
Apellis has successfully guided its C3 complement inhibitor Pegcetacoplan to an approval in paroxysmal nocturnal hemoglobinuria. In this indication the drug has outperformed multi-billion revenue per
Apellis Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 03'rd Jan 2023
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pre
Apellis (APLS) Files MAA for Pegcetacoplan in GA in Europe
03:02pm, Monday, 19'th Dec 2022
Apellis (APLS) submits a marketing authorization application for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration to the European Medicines Agency.
Apellis Pharmaceuticals: Approval Is Baked Into Valuation
01:11pm, Thursday, 15'th Dec 2022
Apellis Pharmaceuticals, Inc. has an upcoming PDUFA. Data is mixed.
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
04:05pm, Tuesday, 22'nd Nov 2022
WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will
Apellis (APLS) Rises on FDA Acceptance of NDA Amendment for GA
11:17am, Monday, 21'st Nov 2022
The FDA accepts Apellis' (APLS) major amendment to the NDA for pegcetacoplan to treat geographic atrophy secondary to age-related macular degeneration. A decision is now due on Feb 26, 2023.
Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares surged in pre-market deals after the Nasdaq-listed global biopharma announced that the US regulator had accepted the company's amendment to its new dr
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
09:19am, Friday, 18'th Nov 2022
Apellis Pharmaceuticals said Friday the Food and Drug Administration will review its new eye-disease drug in February, and APLS stock surged. The post Apellis Pharmaceuticals Surges On New Review Date
